Infections with the Omicron SARS-CoV-2 variant are rapidly increasing worldwide. Among
174,349 SARS-CoV-2-infected individuals (≥ 12 years), we observed an increased risk of S …

Given the emergence of the SARS-CoV-2 Omicron BA.1 and BA.2 variants and the roll-out
of booster COVID-19 vaccination, evidence is needed on protection conferred by primary …

Several studies report high effectiveness of COVID-19 vaccines against SARS-CoV-2 infection
and severe disease, however an important knowledge gap is the vaccine effectiveness …

We estimated SARS-CoV-2 vaccine effectiveness against onward transmission by comparing
secondary attack rates among household members for vaccinated and unvaccinated index …

The SARS-CoV-2 Omicron variant has a growth advantage over the Delta variant because
of higher transmissibility, immune evasion or shorter serial interval. Using S gene target …

The objective of this study was to estimate vaccine effectiveness (VE) against COVID-19
hospitalization and ICU admission, per period according to dominating SARS-CoV-2 variant (…

The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern (VOCs) break through infection- or vaccine-induced immunity is not well …

Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization in infants.
Underlying risk factors for RSV infection in the general population are not well understood, as …

Background In summer 2022, SARS-CoV-2 Omicron BA.5 became dominant in Europe. In
vitro studies have shown a large reduction of antibody neutralisation for this variant. Aim We …

During the COVID-19 pandemic, contact tracing was used to identify individuals who had
been in contact with a confirmed case so that these contacted individuals could be tested and …